• 

  April 29, 2026

  OHSU Secures $9.2M NIH Grant to Advance Bone Cancer Organs-on-Chips Research

  R.D. Solorzano

• 

  April 24, 2026

  Linton Lifesciences Launches Biofabricated NAMs: Rebuilding the Missing Layer Between Biology and Decision-Making

  R.D. Solorzano

• 

  April 21, 2026

  ARPA-H Is Funding the Regeneration of Human Joints, and the Biofabrication Implications Go Further Than Osteoarthritis

  R.D. Solorzano

• 

  April 9, 2026

  The $150 Bioprinter Extruder That Anyone Can Build

  R.D. Solorzano

• 

  April 8, 2026

  Cellbricks Therapeutics Raises €10M to Advance Biofabricated Tissue Implants for Wound Care and Reconstructive Surgery

  R.D. Solorzano

• 

  April 6, 2026

  NAMs, New Approach Methodologies for Drug Discovery: What It Means for the Future of Alternatives to Animal Testing and Biofabrication

  R.D. Solorzano

• 

  April 5, 2026

  Canada Just Bet Another $280M on Bioprinted Medicines, Here’s What It Means for the Industry

  R.D. Solorzano

• 

  March 8, 2026

  UC San Diego’s ARPA-H Project Targets the A Different Approach for the Bioprinted LIVER Program

  R.D. Solorzano

• 

  March 6, 2026

  Japan Moves Toward First Commercial iPS Cell Therapies

  R.D. Solorzano

• 

  March 3, 2026

  Cellares Raises $257M to Industrialize Cell Therapy Manufacturing

  R.D. Solorzano